MetGen
METGEN designs and markets novel enzymatic solutions for customers working in bio-based materials. MetGen, founded in 2008 and is based in Kaarina, Finland, creates industrial, highly-active, natural catalysts that accelerate chemical reactions. The company uses advances in genetic engineering and microbiology to adapt enzymes to harsh industrial conditions and to handle a variety of lignocellulosic substrates. MetGen aims to be a widely recognized supplier of industrial enzymes, significantly contributing to the economics and sustainability of process industries such as biofuels and renewable chemicals.
Sector
Industrial Biotech
Strategy
Industrial Biotech
Status
Live
Website
www.metgen.com
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.